VEGFA and hyperlipidemia: The background mechanism of successful cancer treatment in a hyperlipidemic canine patient appears to be, at first, a hyperlipidemic state, before the treatment suppresses tumor angiogenesis via the inhibition of VEGF [27], and then, chlorambucil is introduced to treat nasal carcinoma, improving the hyperlipidemia [24] and platelet elevation [23] without damaging the liver, which is not the same result as would be attained with tyrosine kinase inhibitors [25] such as sorafenib (Figure 4).